Biotech Blueprint

Biotech Blueprint

Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
Merck's $6.7B Bet and the First Drug to Reach the Brain in Hunter Syndrome – This Week in Biotech #93
Plus Sarepta's first human proof for gene-silencing in muscular dystrophy, a CDC leadership vacuum, and what it all means for biotech (March 20-26…
 • Katerina Roznik
TrumpRx Price Claims Get Fact-Checked, RFK Jr.’s Vaccine Overhaul Paused, Lilly’s Retatrutide Hits Phase 3 – This Week in Biotech #92
A judge freezes ACIP changes, J&J wins a plaque psoriasis pill approval, and Lilly raises the bar again in obesity and diabetes (Mar 13-19, 2026).
 • Katerina Roznik
This Week in Biotech: Brief Update
On pause for two weeks, back March 20.
 • Katerina Roznik
Novo's CagriSema Loses to Zepbound, Grail Stumbles, FDA Hardens Its Stance – This Week in Biotech #91
CagriSema lost the obesity head-to-head with Lilly's Zepbound, Galleri misses its primary endpoint, and the FDA signals tougher tolerance for invasive…
 • Katerina Roznik
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90
Plus Compass psilocybin Phase 3 win and China’s biotech licensing surge (Feb 13-19, 2026).
 • Katerina Roznik

Deep Dives

View all
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Founder Josep Bassaganya-Riera on omilancor, a gut-restricted oral therapy, precision biomarkers in inflammatory bowel disease, and the TITAN-X AI…
 • Katerina Roznik
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
 • Katerina Roznik
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Moderna and BioNTech deploy AI-driven mRNA to target CMV, EBV, HSV, and personalized neoantigen cancer vaccines. These trials could redefine…
 • Katerina Roznik and The Biotech Capital Compass
The mRNA Revolution: Beyond COVID to Cancer, Flu & Herpes Vaccines
How Moderna and BioNTech are expanding from COVID into CMV, EBV, HSV, and next-gen flu, while scaling personalized cancer vaccines (part 1 of the mRNA…
 • Katerina Roznik and The Biotech Capital Compass
Sarepta, Elevidys, and the Future of AAV Gene Therapy
Part 2 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
 • Katerina Roznik and The Biotech Capital Compass
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
Part 1 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
 • Katerina Roznik
Organoids, AI, and the FDA’s Move Away from Animal Models
Inside the FDA’s push to replace lab animals with human tissues & algorithms — with scientist Dr. Patrick Creisher.
 • Katerina Roznik
New contenders, old headwinds: global biotech looks to China
Western biotech faces a tougher funding climate, while Chinese firms move faster and aim higher, reshaping the industry’s global balance.
 • Katerina Roznik and Erin Mihealsick
Podcasts
Apple Podcasts
Spotify
YouTube
Social Media
X
LinkedIn
Facebook
The latest from
Katerina Roznik
Merck's $6.7B Bet and the First Drug to Reach the Brain in Hunter Syndrome – This Week in Biotech #93
User's avatar
Recommendations
Bio Breakdowns
Bio Breakdowns
Adu Subramanian
The Biotech Tea
The Biotech Tea
Annicka Evans, PhD
The Biotech Capital Compass
The Biotech Capital Compass
The Biotech Capital Compass

Recent posts

View all
Moderna Flu Filing Rejected, Sanofi Replaces CEO, AbbVie Sues Over Botox Medicare Pricing – This Week in Biotech #89
CBER’s Refusal to File jolts FDA predictability, Sanofi swaps CEOs, AbbVie sues over Botox Medicare pricing, and BridgeBio’s Phase 3 win contrasts with…
 • Katerina Roznik
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026).
 • Katerina Roznik
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026).
 • Katerina Roznik
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up – This Week in Biotech #86
KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema…
 • Katerina Roznik
Drug Pricing Returns, AI Labs Scale Up, Gene Therapy Pushes Mainstream – This Week in Biotech #85
(Jan 9-15, 2026)
 • Katerina Roznik
Biotech Blueprint
Biotech Blueprint
Biotech & pharma news, stocks, science, startups
Top posts
© 2026 Katerina · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture